The AKAP13 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population providing a loss-of-function model for AKAP13 in HeLa cells. This product consists of a heterogeneous pool of gene-disrupted cells, enabling functional studies without the need for clonal isolation. It serves as a stable platform for dissecting AKAP13-dependent signaling in a well-characterized cervical carcinoma background.
HeLa cells, derived from HPV18-positive human cervical adenocarcinoma, are a standard epithelial model in cancer biology. They harbor functional inactivation of p53 and Rb via E6 and E7 oncoproteins, facilitating investigation of how AKAP13 modulation intersects with HPV-driven malignancy. These adherent cells are easily transfectable and widely used for migration, invasion, and signaling assays.
AKAP13 encodes a scaffolding protein that coordinates cAMP/PKA and Rho GTPase signaling. It binds PKA regulatory subunit RII?? and acts as a RhoA-specific guanine nucleotide exchange factor (GEF), linking G protein-coupled receptor (GPCR) and cAMP signals to RhoA activation. This results in actin polymerization, phosphorylation of cofilin, and actomyosin contractility. Downstream, AKAP13 promotes YAP1/TAZ nuclear accumulation by modulating Hippo pathway components and Rho-dependent cytoskeletal tension. Nuclear YAP/TAZ interact with TEAD to induce target genes such as CTGF and CYR61. Additional AKAP13 interactions include PKC and PP2A, which fine-tune these pathways.
In the context of HeLa cervical carcinoma, AKAP13 knockout allows interrogation of RhoA-driven cytoskeletal dynamics and YAP/TAZ transcriptional activity, both implicated in migration, invasion, and proliferation. This system helps clarify how AKAP13 contributes to cervical adenocarcinoma progression and how its function might differ from its roles in other cancers or in cardiac hypertrophy. The model supports comparative studies between AKAP13-intact and -deficient cells to identify pathway dependencies and potential therapeutic vulnerabilities.
Researchers can employ western blotting for AKAP13, phospho-cofilin, and YAP to confirm kinase activity; RT-qPCR for CTGF and CYR61 to measure YAP/TAZ target gene expression; and immunofluorescence for F-actin to visualize cytoskeletal changes. Functional assays include RhoA activation pull-downs, TEAD luciferase reporters, and transwell migration/invasion tests. Combining genetic knockout with pharmacological inhibitors of PKA or RhoA enables dose-response and drug target validation studies. For more details, please contact Ascent Research.
